SCHEMBL1146355

SCHEMBL1146355

COc1cc(CCOCC(C)(C)[SiH](C)C)c(OC)cc1Br

nearest known ligand 0.51

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 18/20 0.51
HTR2C P28335 5/20 0.51
TAAR1 Q96RJ0 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6713069 0.88 HTR2A (0.38) HTR2AHTR2CTAAR1
SCHEMBL2497068 0.80 MAPT (0.41)
SCHEMBL4204829 0.77 HTR2A (0.62) HTR2AHTR2CTAAR1
SCHEMBL21356175 0.74
SCHEMBL22070712 0.74 TAAR1 (0.41) TAAR1
SCHEMBL21356241 0.72 NOS3 (0.33)
SCHEMBL1146357 0.71 HTR2A (0.54) HTR2AHTR2CTAAR1
SCHEMBL14488042 0.71
SCHEMBL1430161 0.70 PYCR1 (0.41) HTR2A
SCHEMBL2497155 0.70 CA2 (0.34) HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7888374-B2 Inhibitors of c-jun N-terminal kinases ABBOTT LABORATORIES (US) 2011-02-15 US disclosed
WO-2006083673-A2 PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF C-JUN N-TERMINAL KINASES ABBOTT LABORATORIES (US) 2006-08-10 WO disclosed
US-20060173050-A1 Inhibitors of c-Jun N-terminal kinases ABBVIE INC. 2006-08-03 US disclosed
US-20040077853-A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines PFIZER INC. 2004-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173050-A1 Inhibitors of c-Jun N-terminal kinases MAPKAPK3, MAP3K3, MAPK3 HTR2A 4370/4885HTR2C 3842/4885TAAR1 4002/4885
US-20040077853-A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines NOS3, NOS1, NOS2 HTR2A 816/4885HTR2C 1532/4885TAAR1 572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.